In a Phase 1 dose-expansion cohort of previously treated KRAS G12D non-small cell lung cancersmall cell lung cancer, zoldonrasib delivered a confirmed objective response rate of 52% in an efficacy-evaluable subset (n=27) with prior immune checkpoint inhibitor and platinum chemotherapy and no prior docetaxel. Disease control reached 93%, median time to response was 1.4 months, and median duration of response was not yet estimable with a lower bound of 8.3 months. Median progression-free survival was 11.1 months, with an estimated 12‑month PFS rate of 48%. Overall survival remained immature; the 12‑month OS rate was 73%. Safety was manageable at the 1200 mg once-daily recommended Phase 2 dose, with predominantly low-grade gastrointestinal events, Grade 3 treatment-related adverse events in 13%, treatment discontinuation in 5%, no Grade 4/5 events, and mean dose intensity of 94%.
The update, presented at AACR, marks the most detailed monotherapy readout to date for a selective RAS(ON) G12D inhibitor in NSCLC. The multicenter, open-label Phase 1 trial enrolled 40 KRAS G12D NSCLC patients evaluable for safety; efficacy analyses focused on the 27 patients with standard prior exposure to immunotherapy and platinum doublet, excluding those previously treated with docetaxel. The dataset establishes clinical activity and tolerability at the recommended dose, setting the stage for expansion across monotherapy and combination cohorts and informing a registrational path.
Strategically, the move targets a sizable and underserved molecular segment. KRAS G12D is the most prevalent RAS alteration yet lacks an approved targeted therapy, and the post–PD‑1/platinum setting remains dominated by docetaxel-based regimens with modest efficacy and known toxicity. While the cross-trial comparisons are imperfect, the 52% response rate and 11‑month PFS benchmark substantially above historical docetaxel performance will fuel a case for rapid advancement. The exclusion of prior docetaxel in the efficacy set, however, will draw scrutiny in future regulatory dialogues and underscores the need for randomized data. In parallel, the company’s broader RAS(ON) portfolio and planned combinations, including with a multi‑selective RAS inhibitor, signal an intention to defend share across lines of therapy and preempt resistance, but at the cost of added trial complexity.
For sites, the operational message is clear: genomic identification becomes pipeline-critical. With KRAS G12D comprising a small fraction of NSCLC, prescreening infrastructure, rapid NGS turnaround, and centralized testing or ctDNA triage will determine accrual velocity. The once-daily oral regimen and largely outpatient AE profile are conducive to community site participation, but proactive management of gastrointestinal events and dose interruptions will be important to maintain dose intensity. CROs should anticipate a swift transition into randomized cohorts against docetaxel or docetaxel plus ramucirumab, as well as staggered, safety‑gated combination arms that demand tight pharmacovigilance, adaptive governance, and DSMB oversight. Diagnostic partners will be central if a companion diagnostic is pursued to standardize KRAS G12D detection ahead of pivotal studies.
Next, attention will shift to durability curves, subgroup consistency, and resistance mapping as the dataset matures. Randomized design choices will signal regulatory intent: a clean monotherapy head‑to‑head in the post‑PD‑1/platinum setting is the most straightforward route given current FDA expectations, with accelerated pathways unlikely without confirmatory infrastructure in place. Watch for expansion into earlier lines or maintenance strategies and for combination safety signals that could constrain breadth. On execution, global site activation, biomarker funnel management, and oral supply reliability at the 1200 mg dose will be decisive. The pivotal question is whether the Phase 1 signal holds in a docetaxel‑controlled trial; if it does, KRAS G12D NSCLC could move from a diagnostic footnote to a targeted treatment lane within standard lung cancer workflows.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
